NCT05885022 Feasibility Clinical Evaluation of the Calibreye System
| NCT ID | NCT05885022 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Myra Vision Inc. |
| Condition | Glaucoma, Open-Angle |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-05-31 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2023-05-31 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the safety and feasibility of the Calibreye System in patients with open angle glaucoma.
Eligibility Criteria
Inclusion Criteria: * Open angle, pseudoexfoliative or pigmentary glaucoma * IOP at preoperative visit of ≥ 18mmHg and ≤ 45mmHg * Visual field mean deviation score of -3dB or worse * Area of healthy, free and mobile conjunctiva in the target quadrant * Shaffer angle grade ≥ 3 in the target quadrant Exclusion Criteria: * Angle closure glaucoma * Congenital, neovascular or other secondary glaucomas * Previous intraocular surgery (with the exception of laser trabeculoplasty or uncomplicated phacoemulsification with IOL occurring \> 3 months prior to the preoperative visit) * Previous glaucoma shunt/valve in the target quadrant * Clinically significant inflammation or infection in the study eye within 30 days prior to the preoperative visit * History of corneal surgery, corneal opacities or corneal disease * Active diabetic retinopathy
Contact & Investigator
Keith Barton, MD
STUDY CHAIR
Moorfields Eye Hospital NHS Foundation Trust
Frequently Asked Questions
Who can join the NCT05885022 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glaucoma, Open-Angle. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05885022 currently recruiting?
Yes, NCT05885022 is actively recruiting participants. Contact the research team at info@myravision.com for enrollment information.
Where is the NCT05885022 trial being conducted?
This trial is being conducted at Chennai, India, Chihuahua City, Mexico, Puebla City, Mexico, Panama City, Panama.
Who is sponsoring the NCT05885022 clinical trial?
NCT05885022 is sponsored by Myra Vision Inc.. The principal investigator is Keith Barton, MD at Moorfields Eye Hospital NHS Foundation Trust. The trial plans to enroll 60 participants.